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Acute kidney injury (AKI) occurs in about half of patients in
septic shock and the mortality of AKI with sepsis is extremely
high. An effective therapeutic intervention is urgently
required. Statins are 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors that also have pleiotropic actions. They
have been reported to increase the survival of septic or
infectious patients. But the effect of simvastatin, a widely
used statin, on sepsis-induced AKI is unknown. The effects of
simvastatin and tumor necrosis factor (TNF)-a neutralizing
antibody were studied in a clinically relevant model of
sepsis-induced AKI using cecal ligation and puncture (CLP) in
elderly mice. Simvastatin significantly improved CLP-induced
mortality and AKI. Simvastatin attenuated CLP-induced
tubular damage and reversed CLP-induced reduction of
intrarenal microvascular perfusion and renal tubular
hypoxia at 24 h. Simvastatin also restored towards normal
CLP-induced renal vascular protein leak and serum TNF-a.
Neither delayed simvastatin therapy nor TNF-a neutralizing
antibody improved CLP-induced AKI. Simvastatin improved
sepsis-induced AKI by direct effects on the renal vasculature,
reversal of tubular hypoxia, and had a systemic
anti-inflammatory effect.
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Acute kidney injury (AKI) is a common life-threatening
disease, whose mortality has remained at about 45% over
three decades, despite advances in supportive care. Sepsis is a
contributing factor in about half of patients of severe AKI.1
Septic shock is the most common contributing factor to AKI
in intensive care unit.2 Acute kidney injury occurs in half of
septic shock patients whose blood cultures are positive.3 The
mortality is higher in AKI patients with sepsis (75%) than
in those without sepsis (45%).4 Acute kidney injury inde-
pendently increases the morbidity and mortality, although
other organ failures also contribute.5 Thus, the strategy
of treatment for sepsis-induced AKI is urgently required.
Activated protein C decreases mortality from severe sepsis,6
and intensive insulin therapy or early goal-directed therapy,
including early resuscitation, is beneficial in patients with
severe sepsis or septic shock.7,8 However, there are no drugs
to prevent or treat sepsis-induced AKI.9,10
We have recently developed a clinically relevant sepsis-
induced AKI model based on a classic cecal ligation and
puncture (CLP) model of polymicrobial sepsis that can be
used to screen drugs and investigate the pathogenesis of
sepsis. CLP differs from endotoxin injection models because
there is bacterial infection that mimics human sepsis.11–13
Serum creatinine starts to increase at 12 h but not 6 h after
CLP, although tubular damage can be detected at 6 h by
magnetic resonance imaging techniques14 and renal cyr61
expression, a tubular damage marker.15 The renal pathophysio-
logy after CLP is currently unknown.
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins) such as simvastatin have pleiotropic effects indepen-
dent of lipid lowering.16–18 Statin therapy has clinically
beneficial effects on cardiovascular, cerebrovascular and acute
and chronic kidney diseases via diverse effects.17,19–21 The
protective effects of statins on both human and animal sepsis
have been recently shown. A retrospective study in humans
reported that statin therapy reduced both overall and attri-
butable mortality in patients with bacteremia.22 A controlled
study revealed that prior statin therapy was associated with a
reduction of severe sepsis and intensive care unit admission.23
In animals, simvastatin improved survival in a murine CLP
model.24,25 Despite these observations, the possible role of
statins on sepsis-induced AKI remains unknown.
In the present study, we investigated whether simvastatin
has an effect on sepsis-induced AKI and studied its
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mechanism of action. Specifically, we investigated renal
vascular permeability, microperfusion, tubular hypoxia and
histologic damage. As simvastatin decreased circulating
tumor necrosis factor (TNF)-a during sepsis, treatment with
anti-TNF-a antibody was examined.
RESULTS
Effect of simvastatin on sepsis-induced mortality and acute
kidney injury
To determine whether simvastatin had an effect on CLP-
induced mortality and renal dysfunction in aged mice treated
with fluid and antibiotics, we measured survival and renal
function. The survival for mice treated with saline was 100% at
24 h, 42% at 48 h and 26% at 72 h after CLP. The survival for
aged mice treated with simvastatin was 95% at 24 h, 84% at 48 h
and 73% at 72 h (Figure 1). Simvastatin significantly improved
survival after CLP. This survival advantage is consistent with
the previous reports24,25 of the effect of simvastatin on sepsis
in mice. However, previous studies did not evaluate renal
function. Serum creatinine and blood urea nitrogen (BUN)
were significantly increased at 6 h after CLP compared to sham
and further worsened at 24 h. Prior statin treatment signifi-
cantly prevented the renal dysfunction at 24 h but not 6 h after
CLP, as detected by BUN and high-performance liquid
chromatography serum creatinine (Figure 2).
Effect of simvastatin on sepsis-induced tubular damage
As reported previously, CLP caused very subtle changes in
renal histology consisting of patchy tubular vacuolization but
no thrombosis, tubular necrosis or cast formation.15 The
renal histology in both of the cortex and the outer stripe of
the outer medulla (OSOM) worsened significantly after CLP
(Figure 3). Simvastatin significantly prevented the deteriora-
tion of tubular damage induced by CLP in both the cortex
and the OSOM (Figure 3).
Effect of simvastatin on sepsis-induced vascular permeability
Changes in vascular permeability are thought to be important
in the pathogenesis of sepsis-induced organ injury.26
Lipopolysaccharide injection, which is another septic model,
increases vascular permeability in various organs, including
kidney, lung, liver and heart.24,27–29 However, the renal
vascular permeability after CLP is unknown. Therefore,
vascular permeability was assessed by Evans blue dye (EBD)
leakage. Since CLP did not significantly change vascular
permeability at 2 h after CLP (data not shown), we evaluated
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Figure 1 | Effect of simvastatin on survival after CLP. Aged mice
were subjected to CLP. Simvastatin (40 mg/kg) or vehicle was
administered for 3 days before CLP. Open circles indicate CLP group
(N¼ 19). Closed circles indicate statinþCLP group (N¼ 19) (Po0.05).
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Figure 2 | Effect of simvastatin on renal function following CLP
surgery. Mice were treated as in Figure 1. Mice were killed at
indicated times for measurement of (a) serum BUN and creatinine by
(b) HPLC serum creatinine. Closed circles indicate CLP group. Open
circles indicate statinþCLP group. Closed squares indicate sham
group. Values are mean7s.e. (N¼ 6–16 per group). #Po0.05 vs CLP.
##Po0.05 vs sham.
g
#
#
##
##
Sham
Tu
bu
la
r d
am
ag
e 
sc
or
e 
Tu
bu
la
r d
am
ag
e 
sc
or
e 
CLP Statin+CLP Sham CLP Statin+CLP
0.0
0.2
0.4
0.0
0.1
0.2
Cortex OSOM
a b c
d e f
Figure 3 | Effect of simvastatin on renal histology following CLP
surgery. Mice were treated as in Figure 1. Mice were killed at 24 h
after surgery. Histology of cortex in (a, d) Sham group, (b, e) CLP
group, (c, f) statinþCLP group; original magnification: (a–c)  200,
(d–f)  400. (g) The tubular damage score (see Materials and
Methods section) was measured in the cortex (left panel) and the
OSOM (right panel). Values are mean7s.e. (N¼ 6–16 per group).
#Po0.05 vs CLP. ##Po0.05 vs sham.
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it at 6 and 24 h after surgery. Renal vascular permeability was
similar at 6 and 24 h in sham mice. CLP significantly
increased renal vascular permeability at 6 h and remained
high at 24 h (Figure 4). Simvastatin significantly decreased
the CLP-induced increase in renal vascular permeability at
24 h but not at 6 h after CLP.
Effect of simvastatin on renal tubular hypoxia
Tissue hypoxia is thought to be a dominant factor in organ
dysfunction of sepsis.30 Therefore, we assessed renal tubular
hypoxia by pimonidazole incorporation, which is considered
to react with cellular proteins at oxygen tensions below
10 mm Hg.31 Pimonidazole incorporation was detected in the
tubules of the cortex and the OSOM, but not in the inner
stripe of the OSOM or inner medulla after CLP (Figure 5).
Pimonidazole incorporation was significantly increased in
both the cortex and the OSOM at 24 h after CLP (Figure 5).
Simvastatin decreased pimonidazole incorporation in both
the cortex and the OSOM at 24 h. These findings suggest
that CLP caused renal hypoxia at 24 h and that simvastatin
improved renal hypoxia.
Effect of simvastatin on intrarenal microcirculation
Since simvastatin improved CLP-induced renal hypoxia at
24 h, we hypothesized that simvastatin might have a vascular
effect during the late phase of CLP. Therefore, we evaluated
perfusion of the renal microcirculation by physiologic
infusion of fluorescein isothiocyanate-labeled lectin, which
binds to the capillary endothelium. In sham-surgery animals,
peritubular capillaries were clearly detected in the cortex
and in the OSOM. Perfused capillaries were decreased in
the cortex and the OSOM at 24 h after CLP (Figure 6).
Simvastatin partially reversed the decrease in peritubular
capillary flow in the cortex and in the OSOM at 24 h after
CLP (Figure 6). As a control for lectin binding, we evaluated
fluorescein isothiocyanate-labeled lectin binding to unper-
fused kidney sections to confirm the ability of endothelium
to bind lectin after CLP. There was no difference in direct,
topically applied lectin staining between CLP and sham
sections (data not shown). Therefore, the changes shown here
can be attributed to altered perfusion, and not to changes in
lectin binding.
Effect of short-term administration of simvastatin on serum
lipids
CLP did not significantly alter serum cholesterol or
triglyceride at 24 h when compared to sham (serum
cholesterol, 6276.2 vs 7274.9 mg/ml; serum triglyceride,
4476.0 vs 59.278.3 mg/ml). There was no significant
difference in serum cholesterol and triglyceride at 24 h
between statinþCLP and CLP groups (serum cholesterol,
6276.2 vs 55.473.9 mg/dl; serum triglyceride, 4476.0 vs
4072.0 mg/dl). CLP significantly increased serum CK at 24 h
as reported previously 15 (data not shown); however,
simvastatin did not alter serum CK at 24 h after CLP surgery
(data not shown), which suggests that rhabdomyolysis, a
potentially serious side effect of statin therapy,32 did not
occur.
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Figure 4 | Effect of simvastatin on renal vascular permeability.
Mice were treated as in Figure 1. Mice were killed at 24 h after
surgery. Evans blue dye (EBD) leakage in kidney tissue (see Materials
and Methods) was measured at 6 and 24 h following surgery. Values
are mean7s.e. (N¼ 4–6 per group). #Po0.05 vs CLP. ##Po0.05 vs
sham.
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Figure 5 | Effect of simvastatin on pimonidazole incorporation following CLP surgery. Mice were treated as in Figure 1. Mice were killed at
24 h after surgery. Histology of the cortex and OSOM in (a) sham group, (b) CLP group and (c) statinþCLP group. Original magnification,
 200. (d) The hypoxic score (see Materials and Methods) was measured in the cortex and the OSOM. Values are mean7s.e. (N¼ 3–7 per
group). #Po0.05 vs CLP. ##Po0.05 vs sham.
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Effect of tumor necrosis factor-a neutralizing antibody on
sepsis-induced acute kidney injury
Tumor necrosis factor-a is a prototypical proinflammatory
cytokine that is elevated in some sepsis models, and is
considered to be one of the key mediators in developing
AKI in several other renal injury models.33 We found that
simvastatin inhibited serum TNF-a elevation at 24 h after
CLP (Figure 7). We evaluated if simvastatin might improve
renal injury via reduction of circulating TNF-a. However,
neutralization of TNF-a did not significantly reduce serum
BUN and creatinine at 24 h after CLP (Figure 8).
Effect of delayed simvastatin treatment on sepsis-induced
acute kidney injury
We also examined delayed administration of simvastatin
using two different protocols. (1) Simvastatin administered
subcutaneously 40 mg/kg at 6 h after CLP did not improve
serum BUN or creatinine (serum BUN, vehicle: 93.076.5 vs
simvastatin: 102.372.7 mg/dl; serum creatinine, 0.4970.07
vs 0.6970.17 mg/dl, N¼ 6 mice per group). (2) Two doses of
simvastatin administered subcutaneously (40 mg/kg) at 6 and
18 h after CLP did not improve serum BUN or creatinine
(serum BUN, 87.2716.3 vs 89.774.7 mg/dl, serum creati-
nine, 0.3970.08 vs 0.4570.16 mg/dl, N¼ 6 mice per group).
DISCUSSION
We demonstrated that simvastatin, a widely used lipid-lowering
drug, improved sepsis-induced mortality and AKI. Simvastatin
reversed the late renal microvascular injury and microvascular
perfusion defect with corresponding improvement in tissue
oxygenation, and reduced a serum proinflammatory cytokine
(serum TNF-a). These results suggest that simvastatin has both
vascular and anti-inflammatory effects in this model.
Effects of simvastatin in sepsis-induced acute kidney injury
We found that simvastatin significantly improved survival
after CLP in mice, which is consistent with Merx’s previous
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Figure 6 | Effect of simvastatin on renal microvascular perfusion following CLP surgery. Mice were treated as in Figure 1. Mice were killed
at 24 h after surgery. (a–c) Histology of cortex and (d–f) OSOM in (a, d) sham group, (b, e) CLP group and (c, f) statinþCLP group. Original
magnification,  400.
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Figure 7 | Effect of simvastatin on serum TNF-a following CLP
surgery. Mice were treated as in Figure 1. Mice were killed at 24 h
after surgery. Values are mean7s.e. (N¼ 9 per group). #Po0.05
vs CLP.
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Figure 8 | Effect of TNF-a neutralizing antibody on renal function
following CLP surgery. TNF-a neutralizing antibody or normal
mouse Immunoglobulin G was administered at a dose of 800 mg/kg
body weight immediately after CLP. Mice were killed at 24 h after CLP
for measurement of (a) serum BUN and (b) creatinine by HPLC
method. Values are mean7s.e. (N¼ 5–16 per group). #Po0.05
vs sham.
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animal studies.24,25 Two clinical natural history studies
showed that statin usage was associated with reduced
mortality from sepsis and/or bacterial infection.22,23 We also
demonstrated for the first time that simvastatin had a
beneficial effect on sepsis-induced AKI. Pretreatment with
simvastatin improved renal function, as measured by serum
BUN and creatinine (Figure 2). Miyaji et al.15 showed that
CLP caused subtle injury to the renal tubules of the cortex
and the OSOM. Simvastatin also inhibited the patchy tubular
vacuolar degeneration found after CLP in both the cortex
and the OSOM (Figure 3). Statins have been shown to have
beneficial effects in other kidney diseases, including ische-
mia–reperfusion injury, transplantation and chronic kidney
disease.16–18,34,35 Interestingly, these effects, including an
effect on cardiovascular morbidity and mortality, were
independent of lowering serum cholesterol. Although the
site of action of simvastatin is unclear, simvastatin could have
direct tubular effects. The mevalonate pathway or cholesterol
synthesis pathways are activated in cortical tubules after
sepsis induced by lipopolysaccharide or Escherichia coli
injection; however, cholesterol accumulation was not re-
versed by statin therapy.36–38
Vascular effects
During to the rather subtle tubular changes in this model,
and the known effects of statins on the vasculature, we
focused our remaining studies on the renal vasculature. Renal
vascular permeability measured by Evans blue dye (EBD)
extravasation was increased after CLP, and the late increase at
24 h was reversed by simvastatin (Figure 4). Changes in
vascular permeability are thought to be important in the
pathogenesis of sepsis-induced organ injury.26 Increased
vascular permeability can cause compression of peritubular
capillaries,39 hemoconcentration40 and reduced microvascu-
lar flow. Indeed, alteration of vascular permeability is
thought to modulate renal function41 and play an important
functional role in the pathophysiology of ischemic AKI.42,43
Vascular permeability may be altered by several multiple
factors, including the interaction between activated leuko-
cytes and the endothelium, endothelial NO synthase, vascular
endothelial growth factor, angiopoietins, shear stress and
matrix metalloproteinases,42,44,45 which might in turn be
therapeutic targets in sepsis. Statins have been shown to
protect the endothelium with preservation of endothelial NO
synthase function and to regulate several mediators asso-
ciated with vascular permeability, such as vascular endothelial
growth factor and matrix metalloproteinases.17,34 Simvastatin
enhanced endothelial NO synthase expression and improved
vascular permeability in lungs subjected to ischemia–reperfu-
sion injury.46
Interestingly, in our studies, simvastatin did not improve
vascular permeability at 6 h, although vascular permeability
was improved at 24 h (Figure 4). The late reversal was quite
unexpected, and suggests that prolonged increases in vascular
permeability may contribute to renal dysfunction as recently
proposed in ischemic injury.47
We next focused on renal microperfusion and hypoxia,
two consequences of altered vascular permeability. We
detected decreased renal microvascular perfusion measured
by fluorescein isothiocyanate-lectin infusion (Figure 6) and
renal tubular hypoxia measured by pimonidazole staining
(Figure 5) at 24 h after CLP. Interestingly, both microvascular
hypoperfusion and tubular hypoxia were found in both
the cortex and the OSOM at 24 h. A similar loss of global
tubular function was detected by dendrimer contrast
magnetic resonance imaging after CLP.14 Taken together,
our data suggest that increased microvascular permeability
and global worsening of renal microperfusion and tubular
hypoxia might be responsible for developing AKI after CLP,
since tissue hypoperfusion and hypoxia are considered to
be dominant factors in organ dysfunction of sepsis.30,48 Also,
the global pattern of tubular and vascular injury differs
from ischemia–reperfusion injury, which is limited to
the OSOM.43,49,50 On the other hand, this reduced renal
microvascular perfusion might contribute to reduced tubular
damage in our model because reduced cellular metabolism
might increase cell survival.51
Another late effect of simvastatin was that it reversed the
microperfusion defect and tubular hypoxia at 24 h after CLP
(Figures 5 and 6). This reversal might be caused by beneficial
hemodynamic effects and/or local effects on renal tubular or
microvasculature. For example, simvastatin preserved cardiac
function and improved hemodynamic stability24,25 in a CLP
model, although renal end points were not measured.
Simvastatin could decrease tubular oxygen consumption
since it has been shown to reduce cardiac oxygen consump-
tion.52,53 However, that would not easily account for the
reversal effect. Statins may also have direct vascular protective
effects via preservation of endothelial function, in part,
mediated by endothelial NO synthase.54 It is likely that
simvastatin has a direct effect on the vasculature since renal
vascular permeability was restored towards normal after CLP
by simvastatin (Figure 4).
Inflammatory effects
Statins also have anti-inflammatory effects.17,20,21,34 We
found that simvastatin inhibited serum TNF-a elevation at
24 h after CLP (Figure 7). Inhibition of the TNF-a pathway
reduced kidney injury in lipopolysaccharide model.55,56
However, anti-TNF-a treatment does not decrease mortality
in CLP mice,57,58 and did not improve sepsis-induced AKI in
our studies (Figure 8). Although anti-TNF-a did improve
sepsis-induced AKI in a small human study,59,the role of
TNF-a in sepsis is still controversial.
Effect of delayed administration of simvastatin on
sepsis-induced acute kidney injury
A recent study found that delayed administration of
simvastatin starting at 6 h improved mortality in a slightly
different CLP model.25 However, we found that delayed
administration of simvastatin starting at 6 h after CLP
did not improve renal function. How to reconcile these
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observations is not clear. Conceivably, delayed administration
of simvastatin could have a beneficial effect on mortality but
not kidney injury. Alternatively, subtle differences between
animal models might be responsible.
CONCLUSION
We showed that simvastasin improved sepsis-induced
mortality and AKI. The mechanism of its renal protection
may include effects on systemic circulation, direct effects on
the renal vasculature and subsequent reversal of tubular
hypoxia and a systemic anti-inflammatory action. The
advantage of simvastatin in clinical settings is that it is
clinically well established and already widely used, has an
adequate safety profile in septic patients22,23 and is relatively
inexpensive. There are clinical situations where preventive
therapy with simvastatin might be useful. For example, one
could prophylactically administer simvastatin to septic
patients who have been identified to be at high risk for
sepsis-induced AKI by either clinical characteristics or
biomarker findings. Thus, simvastatin may be a potential
preventive intervention for sepsis-induced AKI.
MATERIALS AND METHODS
Animals
Animal care followed the National Institutes of Health criteria for
the care and use of laboratory animals in research (K100-MDB-02).
Male (38–44 week old) C57BL/6 mice (National Institutes of Health,
Frederick, MD, USA) had free access to water and chow before and
after surgery and were housed individually.
Polymicrobial CLP sepsis-induced acute kidney injury
CLP was performed as described previously with small modifica-
tions.15 Briefly, a 4–0 silk ligature was placed 15 mm from the cecal
tip after laparotomy under isoflurane anesthesia. The cecum was
punctured twice with a 21-gauge needle and gently squeezed to
express a small amount of fecal material, and then returned to the
central abdominal cavity. In sham-operated animals, the cecum was
located, but neither ligated nor punctured. The abdominal incision
was closed in two layers with 6–0 nylon sutures. After surgery, 1 ml
per 25 g body weight of prewarmed normal saline was given
subcutaneously.13 All animals received antibiotic and fluid therapy
subcutaneously (imipenem/cilastatin; 14 mg/kg in 1.5 ml of 2/3
saline at 6 h and 7 mg/kg in 1.5 ml of 2/3 saline at 18 h after surgery).
At 24 h after surgery, blood was collected from the abdominal aorta
for measurement of serum creatinine, BUN and TNF-a. Serum
creatinine was measured by high-performance liquid chromatogra-
phy.60 Serum BUN and TNF-a were measured as described
previously.15 Kidneys were fixed in 10% formalin or snap-frozen
in liquid nitrogen before storage at 801C until further study.
Treatment of simvastatin and TNF-a antibody
Simvastatin (EMD Biosciences, Inc., CA, USA) was prepared by
dissolving 10 mg of simvastatin in 500ml of ethanol and 0.407ml of
1 N NaOH, incubating at 501C for 2 h and then storing at 801C.
The stock solution was diluted with saline at a ratio of 1:20 and
adjusted to pH 7.2 before use. The vehicle solution was prepared in
the same way without simvastatin. For pretreatment studies, mice
were given 40 mg/kg simvastatin or vehicle solution by oral gavage
for 3 consecutive days before the surgery; simvastatin was not given
after surgery. For post-treatment studies, mice were given 40 mg/kg
or vehicle solution subcutaneously once at 6 h, or twice at 6 and 18 h
after surgery.
TNF-a neutralizing antibody (R&D Systems, Inc., MN, USA) was
administered as a single intraperitoneal injection at a dose of 800mg/kg
body weight61 immediately after CLP. Normal mouse immuno-
globulin G was used as a control.
Survival study
Survival was assessed every 6–12 h starting 6 h after surgery.
Antibiotic injection and fluid resuscitation were started 6 h after
surgery by subcutaneous injection, and then repeated every 12 h for
4 days.
Renal histology analysis
Tissue was fixed in 10% formalin and embedded in paraffin. Sections
of 4mm were stained with periodic acid-Schiff reagent. Histologic
changes in the cortex and the OSOM were assessed by quantitative
measurements of tissue damage. As tubular damage was mainly
vacuolization, the damage was defined as tubular vacuolar degene-
ration. The degree of kidney damage was estimated at  400
magnification using more than 100 randomly selected tubules for each
animal by following the criteria: 0, normal; 1, area of damageo25% of
tubules; 2, damage involving 25–50% of tubules; 3, damage involving
50–75% of tubules; 4, 75–100% of tubules being affected.
Assessment of renal microvascular protein leak using Evans
blue dye
The microvascular leakage of EBD was assessed as described
previously62–64 with slight modifications. At 30 min before killing,
mice were injected intravenously with EBD (Sigma-Aldrich, MO,
USA) 2 ml/kg at 1% in 0.9% sodium chloride via a tail vein. At
killing, mice were perfused with phosphate-buffered saline (PBS)
through the left ventricle until blood was totally eliminated. The
kidneys were weighed, snap-frozen in liquid nitrogen, and stored at
801C. The kidneys were homogenized in 1mL formamide and
incubated at 551C for 18 h. The supernatant was collected after
centrifugation at 10 000 g for 30 min. The amount of EBD in the
supernatant was analyzed by measuring absorbance at 620 nm.
Results were calculated from a standard curve of EBD and expressed
as micrograms of EBD per gram of kidney (wet weight).
Assessment of renal hypoxia
Renal hypoxia was assessed by pimonidazole immunohistochem-
istry. Pimonidazole (Chemicon International, Inc. CA, USA) was
administered administrated intraperitoneally at the dose of 60 mg/kg
2 h before killing. Kidneys were bisected and immersed, gently
agitated in 10% formalin at room temperature for 24 h, and
processed for paraffin embedding. sections of 4 mm were processed
by the manufacturer’s procedure. All procedures were conducted at
room temperature. Briefly, the sections were incubated with 0.01%
pronase (Biomeda, CA, USA) for 5 min after deparaffinization and
peroxidase quenching. After washing with PBS, the sections were
incubated with 10% normal donkey serum in 1% bovine serum
albumin) in PBS for 20 min. The sections were sequentially
incubated with Hypoxyprobe-1 Mab1 (1:100 dilution with PBS
containing 1% bovine serum albumin) for 2 h, biotin-conjugated
donkey anti-mouse immunoglobulin G (1:1000 dilution, Jackson
Immunolaboratory, PA, USA) for 30 min, peroxidase-conjugated
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streptavidin for 30 min, 3,30-diaminobenzaidine, then counter-
statined with hematoxylin. No staining was detected without
Mab1 (not shown). Renal hypoxia was evaluated by semiquantitative
measurements of pimonidazole staining on tubules of the cortex and
the outer stripe of the OSOM. The degree of pimonidazole staining
was estimated at  400 magnification using more than five
randomly selected fields for each animal by the following criteria
according to the intensity and the extent of positive cells: 0, no
staining; 1, slight, 2; moderate, 3; severe staining.
Analysis of renal microvasculature by fluorescein isothio-
cyanate-labeled lectin perfusion
To identify vessels with intact blood flow, the renal vasculature was
identified with a lectin that binds uniformly to the luminal surface
of endothelial cells.65–67 Fluorescein isothiocyanate-Lycopersicon
Esculentum lectin (30 mg, Vector Laboratories, CA, USA) was
injected via a tail vein 5 min before killing. The vasculature was
perfused with PBS via the left ventricle, and the kidneys were
harvested after intracardiac perfusion of PBS and fixed with 2%
paraformaldehyde for 1 h, followed by freezing in optimum cutting
temperature compound.
Cryosections of 5 mm were evaluated with a Leica DMRXE
fluorescence microscope.
Statistical analysis
Differences between groups were examined for statistical signifi-
cance by analysis of variance with a multiple comparison correction.
Comparisons between survival curves were made using a log-rank
test (Prism 4.0, Graphpad Software, Inc., CA, USA). A P-value
o0.05 was accepted as statistically significant.
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